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OBJECTIVES: To investigate the effect of laser pan-retinal photocoagulation with or without intravitreal
bevacizumab injections on macular choroidal thickness parameters in eyes with high-risk proliferative diabetic
retinopathy.
METHODS: High-risk proliferative diabetic retinopathy patients undergoing laser treatment were prospectively
enrolled in this study. One eye was randomly selected for laser treatment combined with bevacizumab
injections, study group, whereas the corresponding eye was subjected to laser treatment alone, control group.
Spectral-domain optical coherence tomography with enhanced depth imaging was used to measure the macular
choroidal thickness prior to and 1 month after treatment. Measurements in both groups were compared.
Clinicaltrials.gov: NCT01389505.
RESULTS: Nineteen patients (38 eyes) with a mean±standard deviation age of 53.4±9.3 years were evaluated,
and choroidal thickness measurements for 15 patients were used for comparison. The greatest measurement
before treatment was the subfoveal choroidal thickness (341.68±67.66 mm and 345.79±83.66 mm for the study
and control groups, respectively). No significant difference between groups was found in terms of macular
choroidal thickness measurements at baseline or after treatment. However, within-group comparisons revealed
a significant increase in choroidal thickness parameters in 10 measurements in the study group and in only 5
temporal measurements in the control group when 1-month follow-up measurements were compared to
baseline values.
CONCLUSIONS: The macular choroidal thickness does not appear to be significantly influenced by laser
treatment alone but increases significantly when associated with bevacizumab injections in patients with
proliferative diabetic retinopathy and macular edema. Because bevacizumab injections reduce short-term laser
pan-retinal photocoagulation-induced macular edema, our findings suggest that the choroid participates in its
pathogenesis.
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’ INTRODUCTION
Diabetes mellitus (DM) is an important metabolic disease
that is often associated with injury to several ocular
structures. Diabetic retinopathy (DR) is one of its most
common chronic microvascular complications (1) and one of
the leading causes of new-onset blindness in industrialized
and middle-income countries (2). Diabetic macular edema
(DME) and proliferative diabetic retinopathy (PDR) are the
primary disorders responsible for vision loss (3).
Laser pan-retinal photocoagulation (PRP) is the primary
treatment modality for preventing vision loss in patients
with PDR (4, 5). Although PRP effectively reduces retinal
neovascularization, it is associated with the release of cyto-
kines, including vascular endothelial growth factor (VEGF),DOI: 10.6061/clinics/2017(02)03
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which may be related to adverse effects in the retina, includ-
ing ME (6), thereby causing transient or permanent visual
acuity (7-9) and contrast sensitivity loss (10). Therefore, many
researchers have used anti-VEGF drugs such as intravitreal
bevacizumab (IVB) injections with promising results to prevent
the development of PRP-related ME (8, 9).
Previous studies have indicated that DM may also affect
the choroid via obstruction of the choriocapillaris, vascular
degeneration, and the development of choroidal aneurysms
and neovascularization that may be present even before the
onset of DR (11-13). Moreover, because the outer retinal
layers are essentially nourished by the choroid, some authors
believe that choroidal changes play an important role in the
development of DR (11, 14, 15).
Most previous studies evaluating possible involvement
of the choroid in patients with DM were performed using
indocyanine green angiography (14, 16). More recently, how-
ever, optical coherence tomography (OCT) has been intro-
duced as an important and accurate method for estimating
macular CT (17).
In relation to the changes in macular CT for PDR patients
treated with PRP with or without anti-VEGF, the published
data are still inconsistent likely due to differences in samples
and the presence or absence of DME. The only finding that
has been confirmed is that PRP causes macular CT thinning
in long-term follow-ups (18-22).
Despite the vast literature addressing the effects of PRP on
the retina, previous OCT studies have not addressed the
possible effects of PRP with or without IVB injections on the
macular CT measurements of high-risk PDR patients. Thus,
we prospectively investigated the effects of PRP alone or
with the adjuvant use of IVB injections on macular CT
measurements in patients with high-risk PDR.
’ METHODS
This trial applied an interventional, prospective, masked,
and randomized study design. The study followed the
principles of the Declaration of Helsinki and was approved
by the Institutional Review Board of the Ethics Committee of
our institution. All participants signed an informed consent
form. Clinicaltrials.gov: NCT01389505.
The inclusion criteria for the study were best corrected
visual acuity (BCVA)X20/200, type 2 DM, and similar high-
risk PDR in both eyes with or without DME. The exclusion
criteria were pretreatment of diabetic retinopathy (laser
photocoagulation or intraocular surgery), vitreous hemor-
rhage, vitreous-retinal interface alteration (epiretinal mem-
brane, macular hole, or vitreoretinal traction syndrome),
active external eye disease, systolic or diastolic blood pres-
sures greater than 180 or 110 mm Hg, respectively, A1C
levels exceeding 15%, and chronic renal failure.
Twenty-two patients (13 males) were enrolled in the study.
All patients received a complete clinical evaluation and the
following ophthalmic examinations: BCVA assessment, intrao-
cular pressure measurements, slit-lamp examinations, fundo-
scopy and time-domain (Stratus-OCTs, Carl Zeiss Ophthalmic
System, Inc.; Dublin, California, USA) and spectral-domain
(Spectraliss, Heidelberg Engineering, Heidelberg, Germany)
OCT scanning. Diabetic ME was diagnosed if the OCT foveal
thickness (FT) was X250 mm on Stratus-OCTs measurements
(23). This latter piece of equipment was used to classify ME,
due to the consolidation of its measurements in patients with
DR by other published trials.
Choroidal Thickness Measurement
The Heidelberg Spectralis spectral-domain OCT (SD-OCT)
at 870 nm with enhanced depth imaging (EDI) was used
to measure macular CT, defined as the vertical distance
between the posterior edge of the retinal pigment epithelium
to the choroidal-scleral junction. CT measurements at 500-mm
intervals up to 2,500 mm from the temporal and nasal to the
fovea were used for comparisons. An investigator blinded
to the study design performed all measurements in one
afternoon. On a different occasion, another examiner inde-
pendently measured the same group of OCTs. To calculate
intra- and inter-observer variability, the same two observers
repeated their measurements unaware of the previous results.
The fourth-generation OCT employed was equipped with
a camera that can be used to monitor the stability of patient
fixation. Therefore, the tomograms should occur at the same
point. The images were generated using six macular radial
scans, centered at the fovea at equally spaced angular
orientations, with 20 raster lines spaced 200 mm apart. The
machine rated the quality of the images, and only ratings
greater than 25 were considered high-quality scans. Cross-
sectional images were analyzed using built-in software.
Study design, treatment and follow-up protocol
Both eyes of each patient were included. The first eye was
randomly assigned to the study group to receive PRP with
IVB injections, and the other eye was enrolled in the control
group and received PRP alone. A schematic representation of
the study protocol is shown in Figure 1.
The control group received PRP once per week for 3 con-
secutive weeks beginning on the same day as randomization.
Between 300 and 500 shots were given per episode. The
retinal laser parameters were a spot size of 250 mm, an expo-
sure time between 0.1 and 0.2 msec, and a moderate intensity
(200 to 500 mW)(24). When concomitant DME was present,
it was treated during the first episode of PRP based on Olk
et al. (25) and the ETDRS guidelines (26).
In the study group, on the day of randomization, one eye
received an IVB (1.25 mg/0.05 mL) injection following
standard international guidelines (27). The first PRP episode
was performed after only 1 week, and the second IVB injection
was administered at the end of the third PRP episode. There-
fore, the interval between the two injections was 3 weeks, and
three episodes of PRP were also performed.
The laser treatment for both eyes was performed after
ophthalmic evaluation using a double-frequency Nd:YAG
laser (532 nm; Alcon, Ophthalas 532 EyeLite Laser Photo-
coagulator, Fort Worth, TX, USA) via a 160 Mainster OMRA-
PRP lens (Volk Instruments, Bellevue, CA, USA).
The patients were followed for 1 month. Ophthalmic exami-
nations at the end of a 1-month follow-up visit included
intraocular pressure measurements using a Goldmann appla-
nation tonometer, slit-lamp biomicroscopy, fundus examina-
tion, OCT scanning and fluorescein angiography.
Study outcomes
The primary outcome was a determination of macular CT
measurements of the eyes in the experimental and control
groups at baseline and at a 1-month follow-up; these mea-
surements were then compared between the two groups.
The secondary outcome included a longitudinal com-
parison of macular CT measurements within each group,
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comparing the measurements at baseline with those at the
first-month follow-up visit.
Potential injection-related local side effects, such as ocular
hypertension, lens opacity progression, and anterior chamber
reaction, were reported to evaluate ocular safety. Arterial
thromboembolic events were reported to evaluate systemic
safety.
Statistical analyses
Descriptive statistics included the mean±standard
deviation. The Shapiro–Wilk test was used to evaluate the
normality assumption. Comparisons of macular CT measure-
ments between and within groups were assessed using the
rank-sum and the Wilcoxon signed-rank test, respectively.
An intra-class correlation coefficient (ICC) was calculated
to assess inter- and intra-rater variability for measure-
ments of macular CT. Fisher ’s exact test was applied to
compare the number of significantly different measure-
ments in the treatment and the control group. The level of
statistical significance was defined as po0.05. The ana-
lyses were performed using SPSS, version 15.0 (SPSS Inc.,
Chicago, IL, USA).
’ RESULTS
Twenty-two patients were eligible, and 19 were included
in the study. Three patients were excluded before randomi-
zation, 2 because of unreliable CT measurements and one
because of vitreous hemorrhage. Nineteen patients (38 eyes)
were randomized and treated, but at the one-month follow-
up, 4 patients were excluded (2 because of vitreous hemor-
rhage and 2 because of unreliable CT measurements at
follow-up). The fourth excluded patient had one eye (from
the control group) excluded due to unreliable CT measurements,
whereas the eye subjected to PRP and IVB injections was
suitable for study.
The intra-class correlation coefficient for the macular CT
measurements by the second observer at the fovea, 500 mm
nasal and 500 mm temporal was 0.99 for all three measure-
ments (po0.001), indicating excellent inter-observer varia-
bility. The corresponding value for repeated measurements
by the same reader was 0.98, indicating excellent intra-
observer variability (po0.001).
The mean age ± standard deviation of the 19 patients
was 53.4±9.3 years, and 9 patients (60%) were males. The
average glycated hemoglobin level was 8.89 (range 7.5-9.7).
DM had lasted 17.3±8.7 years, and systemic arterial hyper-
tension had lasted 7.3±6.2 years. The mean initial BCVAwas
0.21±0.21 and 0.21±0.21 logMAR for the study and control
groups, respectively.
DME was present in 11 and 10 eyes of the 15 patients from
the study and control groups, respectively. Table 1 shows
average FT measurements for both groups throughout the
study. A significant increase in FT measurements at a 1-month
follow-up, compared to baseline values, was observed in both
groups.
Between-group comparison
Table 2 shows all CT measurements at baseline and at a
1-month follow-up both in the study and in the control group.
The comparison between the two groups is based on
19 patients at baseline and 15 patients at a 1-month follow-up
(Figure 1). In both groups, CT measurements were greater
for the foveal measurement (341.68±67.66 mm and 345.79±
83.66 mm for the study and control groups, respectively).
Figure 1 - Schematic representation of the study protocol (between-group comparison). *intravitreal bevacizumab; **pan-retinal
photocoagulation.
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The CT increased toward the temporal and decreased toward
the nasal regions from the center of the macula. No signif-
icant difference was found in any comparison between
the two groups at baseline and at the 1-month follow-up
measurement.
Within-group comparison
Table 3 and Figure 2 show an intra-group comparison of
all macular CT measurements before and 1 month after
treatment. For intra-group comparisons, 16 eyes in the study
group and 15 eyes in the control groups were evaluated
before treatment and at the 1-month follow-up. Almost all
macular CT measurements taken in the study group
increased significantly from the baseline when compared to
the 1-month follow-up visit measurement. In contrast, in the
control group, only 5 temporal macular CT measurements
were significantly higher at the 1-month follow-up. Statistical
analysis indicated a significantly greater number of increased
measurements in the treatment group than in the control
group (p=0.024, Fisher’s exact test).
Throughout the study, we did not detect ocular hyperten-
sion, lens opacity progression, anterior chamber reactions, or
thromboembolic events.
’ DISCUSSION
The relationship between the choroid and DR and the
effects of PRP with or without intraocular anti-VEGF agents
on macular CT are not well understood in high-risk PDR
patients. There is conflicting evidence on the effects of
anti-VEGF agents on macular CT, even in patients not
subjected to PRP. Nevertheless, in PDR diabetic patients,
because PRP can increase macular retinal thickness in the
short-term, it is possible that it may also alter macular CT.
Furthermore, in a prospective, non-comparative, 1-month
follow-up study, Takashi et al. (28) observed that PRP
significantly increased choroidal blood volume (CBV) and
choroidal blood flow (CBF) in the foveal region of patients
with DR. The authors suggested that the increased CBV and
CBF after PRP may be explained by local inflammation and
cytokine (e.g., VEGF) release induced by PRP and/or the
regional redistribution of blood flow toward the macula
triggered by PRP (28). In addition, the choriocapillaris and
large choroidal vessel present VEGF receptors (29); VEGF
released soon after PRP can act in choroidal vessels, pro-
moting their dilation and consequently leading to increased
thickness.
Zhang et al. (30) reported that PDR patients who under-
went PRP had an increased CT soon after the completion of
PRP, whereas in DME patients, who likely had higher
concentrations of intraocular VEGF, a significant increase
was not observed. In contrast to this study, a study by
Hwang et al. (31) did not find a significant difference in
macular CT after PRP in early-PDR patients, mostly without
DME. In the current study, we found that eyes subjected to
PRP and two IVB injections had a significantly greater
macular CT increase from baseline to the 1-month follow-up
than eyes in the PRP-alone group (Table 3 and Figure 2).
Roohipoor et al. (19) reported that eyes with PDR treated
with IVB in addition to PRP had a macular CT that decreased
Table 2 - Comparison between macular choroidal thickness measurements of eyes with diabetic retinopathy from the study group and
the control group at baseline and at a 1-month follow-up after treatment.
Choroidal thickness measurements (mm)
Time Group N2500 N2000 N1500 N1000 N500 Fovea T500 T1000 T1500 T2000 T2500
Baseline Study 252.8 274.8 300.6 318.3 336.8 341.7 327.8 304.1 287.4 279.2 264,89
(n=19) Control 246.2 268.5 290.7 313.7 329.7 345.8 335.3 326.9 311.5 286.2 265.3
1 month Study 251.4 281.7 306.5 333.9 350.9 355.7 337.6 319.5 304.1 295.7 284.5
(n=15) Control 234.9 265.2 297.1 320.1 341.6 364.5 358.7 348.8 336.8 319.9 299.4
*po0.05; CT = choroidal thickness; N = nasal; and T = temporal
Table 1 - Foveal thickness measurements for both groups throughout the study.
Groups Time Comparison Foveal thickness (mm) p
Study Baseline - 1 month (16 eyes) 315.56±87.74 - 324.88±68.39 0.029*
Control Baseline - 1 month (15 eyes) 288.20±64.25 - 310.27±90.17 0.011*
*po0.05
Table 3 - Macular choroidal thickness of the nasal, temporal and subfoveal regions at baseline and follow-up throughout the study.
Comparison within groups.
Choroidal thickness measurements (mm)
Groups N2500 N2000 N1500 N1000 N500 Fovea T500 T1000 T1500 T2000 T2500
Study Baseline 243.75 261.31 290.63 309.19 328.19 334.88 326.44 304.38 289.94 281.06 261.25
(n=16) 1 month 250.19 282.88* 313.81* 340.19* 357.19* 362.50* 345.00* 327.31* 312.25* 299.94* 282.81*
Control Baseline 235.07 264.20 286.47 312.73 330.33 347.73 338.47 332.67 320.40 291.67 269.53
(n=15) 1 month 234.93 265.20 297.07 320.13 341.60 364.53 358.67* 348.80* 336.80* 319.87* 299.40*
*po0.05; CT = choroidal thickness; N = nasal and T = temporal
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3 months after the procedure, although no significant abnor-
mality was observed at a 1-month post-treatment measure-
ment. However, they did not classify the stage of PDR, and
their sample included only eyes without DME. In contrast, in
the current study, we found a large majority of patients with
DME and high-risk PDR, likely with high concentrations of
cytokines, including VEGF. Differences in patient selection
and the different effects of the anti-VEGF drug on the retina
and the choroid may explain the differences in the study
results.
We believe that the finding of a greater CT increase at
the end of 1 month in the group subjected to PRP + IVB
injections compared to the group subjected to PRP alone
may be primarily explained by four mechanisms: a) PRP
temporarily increases the macular CBV and CBF (28);
b) increased VEGF concentrations in the choroid, increased
by the laser treatment, may not be completely neutralized in
the choroid by bevacizumab treatment; c) choroidal effusion
is generated by choriocapillaris disruption (32); and d) there
is a possible stabilization effect of bevacizumab on the external
hemato–retinal barrier (EHB) via blockage of VEGF. Elevated
VEGF levels induced by laser treatment may cause a
breakdown of the EHB by allowing a free liquid shift from
and to the choroid and retina; bevacizumab may at least
partially restore EHB function. Because it is known that PRP
promotes a shift of liquid from the periphery of the choroid
to the macular area (8), the bevacizumab-induced stabiliza-
tion of EHB function may prevent the liquid from moving
from the choroid to the retina.
We therefore believe that because laser treatment causes
increased VEGF levels inside the eye leading to a more
significant breakdown of the EHB, fluid may shift from
the choroid to the retina, particularly in eyes with long-
standing DME, which have retinal pigment epithelium that
has been progressively damaged by the presence of fluid.
The use of anti-VEGF bevacizumab treatment as an adjuvant
may, in part, restore the hemato–retinal barrier function,
somehow preventing a fluid shift and therefore contributing
to an increase in choroid thickness, relative to pretreatment
measurements in the study group. This reasoning may
explain why the control group showed less significant
increases in macular CT measurements compared to the
treatment group in the current study; this may also explain
why Regatieri et al. (18) observed macular CT decreases in
patients with long-standing DME and presumably damaged
EHB function.
We understand that the limitations of the present study
include its relatively small sample size, its short follow-up
period and its inclusion of patients with and without DME.
However, we believe that the results of this pilot study may
stimulate further research on the choroidal contribution in
the appearance of DME after PRP.
Figure 2 - Mean macular choroidal thickness measurements from each group at different locations across a horizontal section through
the fovea. This measurement significantly differed at the 1-month follow-up visit compared with the baseline. The error bars represent
1 standard deviation.
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In conclusion, although significant between-group differ-
ences in the macular CT measurements were not observed,
our study indicates that when IVB injections were used as an
adjuvant to PRP in the treatment of PDR, a more pronounced
increase in the macular CTwas observed over a brief follow-
up. Additional larger studies are required to confirm these
findings.
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